Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ropes & Gray LLP
- 23.1 Consent of Ernst & Young LLP
- 23.2 Consent of Ernst & Young LLP
- 23.4 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
- 23.5 Consent of Harris Nesbitt Corp.
- 99.4 Consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated
- 99.5 Form of Genome Therapeutics Corp. Proxy Card
- 99.6 Form of Genesoft Pharmaceuticals, Inc. Proxy Card
- 99.9 Consent of David B. Singer
- 99.10 Consent of Luke B. Evnin
- 99.11 Consent of William J. Rutter
- 99.12 Consent of Vernon R. Loucks, JR.
OSCI similar filings
- 10 Sep 08 Registration of securities issued in business combination transactions
- 15 Mar 07 Registration of securities issued in business combination transactions
- 30 Dec 03 Registration of securities issued in business combination transactions (amended)
- 15 Dec 03 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the reference to our firm under the caption “Experts” in Amendment No. 1 to the Registration Statement (No. 333-111171) on Form S-4 and related Joint Proxy Statement/Prospectus of Genome Therapeutics Corp. and to the incorporation by reference therein of our report dated February 18, 2003, except for Note 13 as to which the date is March 14, 2003, with respect to the consolidated financial statements of Genome Therapeutics Corp. included in its Annual Report (Form 10-K) for the year ended December 31, 2002, filed with the Securities and Exchange Commission.
/s/ ERNST & YOUNG LLP
Boston, Massachusetts
December 29, 2003